Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM(SM) registry

BACKGROUND: Immune related adverse events (irAEs) are associated with immunotherapy for cancer and while results suggest improvement in tumor control and overall survival in those experiencing irAEs, the long-term impact is debated. We evaluated irAE reports related to high dose interleukin-2 therap...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Immunother Cancer
Главные авторы: Curti, Brendan, Daniels, Gregory A., McDermott, David F., Clark, Joseph I., Kaufman, Howard L., Logan, Theodore F., Singh, Jatinder, Kaur, Meenu, Luna, Theresa L., Gregory, Nancy, Morse, Michael A., Wong, Michael K. K., Dutcher, Janice P.
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2017
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5735508/
https://ncbi.nlm.nih.gov/pubmed/29254506
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-017-0307-5
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы